福建广生堂药业股份有限公司 2025 年第三季度报告 证券代码：300436 证券简称：广生堂 公告编号：2025073 福建广生堂药业股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | | | 营业收入（元） | 106,980,494.78 | -1.07% | 315,838,085.22 | -3.21% | ...

证券日报网讯广生堂10月29日在互动平台回答投资者提问时表示，公司将于10月30日发布三季度报告， 请关注公告。 （文章来源：证券日报） ...

尊敬的投资者，您好。公司目前暂无广生中霖单独运作上市的具体计划。 本次广生中霖增资将补充运 营所需资金，通过加快推进在研创新药的研发进程，早日实产品商业化，从而提升广生中霖的内在价 值，为全体广生中霖股东带来可持续的创新回报。公司将按照监管规定及时履行信息披露义务，所有重 大信息请以指定披露媒体公告为准。感谢您的关注！查看更多董秘问答>> 近日福建广生中霖生物科技有限公司完成定增扩股，主要参与方均是国企，请问，公司有计划将该控股 子公司单独运作上市的计划吗？如果不是，资本参与的汇报机制是什么？ 董秘回答(广生堂SZ300436)： 登录新浪财经APP 搜索【信披】查看更多考评等级 投资者提问： 免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 福建广生堂药业股份有限公司（以下简称"公司"）于2025年9月1日召开第五届董事会第十一次会议审议 通过了《关于控股子公司股权转让及增资扩股暨公司放弃优先权的议案》，同意公司创新药控股子公司 福建广生中霖生物科技有限公司（简称"广生中霖"）少数股东股权对外转让及广生中霖增资扩股引入重 要投资者，公司放弃优先购买权和优先认缴出资权事项。本议案在2025年9月17日召开的2025年第二次 临时股东大会决议中获得通过。本次交易完成后，广生中霖注册资本由38,850万元增加至41,823.60万 元，公司对广生中霖持股比例由81.0811%变为75.3163%，广生中霖仍为公司控股子公司，不会导致公 司合并报表范围发生变更。具体内容详见公司披露的《关于控股子公司股权转让及增资扩股暨公司放弃 优先权的公告》（公告编号：2025062）、《关于控股子公司股权转让及增资扩股暨公司放弃优先权的 进展公告》（公告编号：2025068）。 目前广生中霖已收到前述增资扩股投资者全部增资 ...

关于控股子公司股权转让及增资扩股 完成工商变更并取得营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 福建广生堂药业股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召 开第五届董事会第十一次会议审议通过了《关于控股子公司股权转让及增资扩股 暨公司放弃优先权的议案》，同意公司创新药控股子公司福建广生中霖生物科技 有限公司（简称"广生中霖"）少数股东股权对外转让及广生中霖增资扩股引入 重要投资者，公司放弃优先购买权和优先认缴出资权事项。本议案在 2025 年 9 月 17 日召开的 2025 年第二次临时股东大会决议中获得通过。本次交易完成后， 广生中霖注册资本由 38,850 万元增加至 41,823.60 万元，公司对广生中霖持股 比例由 81.0811%变为 75.3163%，广生中霖仍为公司控股子公司，不会导致公司 合并报表范围发生变更。具体内容详见公司披露的《关于控股子公司股权转让及 增资扩股暨公司放弃优先权的公告》（公告编号：2025062）、《关于控股子公 司股权转让及增资扩股暨公司放弃优先权的进展公告》（公告编号：20 ...

Group 1 - The core point of the news is that Guangshentang's stock price dropped by 5.22% to 117.62 CNY per share, with a trading volume of 685 million CNY and a turnover rate of 4.18%, resulting in a total market capitalization of 18.733 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund has increased its holdings. The China Europe Medical Health Mixed A Fund (003095) added 393,100 shares in the second quarter, holding a total of 1.8447 million shares, which accounts for 1.35% of the circulating shares [2] - The estimated floating loss for the China Europe Medical Health Mixed A Fund today is approximately 11.9533 million CNY [2] - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, with a latest scale of 15.638 billion CNY. Year-to-date returns are 22.96%, ranking 3563 out of 8162 in its category, while the one-year return is 17.71%, ranking 4198 out of 8024 [2]

Summary of Conference Call Notes Company and Industry Overview - **Company**: 广生堂 (Guangshengtang) - **Industry**: Innovative Pharmaceuticals, Traditional Chinese Medicine, Medical Devices, CRO (Contract Research Organization) Key Points and Arguments 1. **Market Opportunities in Innovative Pharmaceuticals**: The innovative drug sector is expected to see a new wave of opportunities following irrational market perceptions and rapid digestion of shares, supported by new catalysts and expectations [2][6] 2. **Collaboration with Global Pharma**: Pfizer's CEO expressed willingness to collaborate with Chinese pharmaceutical companies, indicating a strong industry trend that could benefit local firms [2][6] 3. **Potential of Guangshengtang's Products**: Guangshengtang's products 131 and 141 show promise for achieving clinical cure for hepatitis B, with their efficacy recognized both domestically and internationally [2][7][8] 4. **Market Statistics**: In 2022, hepatitis B caused 1.1 million deaths in China, with chronic HPV infections affecting 86 million people, but diagnosis and treatment rates remain low at 22% and 15%, respectively [2][7][8] 5. **Focus on Q4 Opportunities**: Anticipation of catalysts in Q4 includes the digestion of BD expectations, increased spending by multinational corporations before Christmas, and positive data from major conferences [2][6] 6. **Performance of Traditional Chinese Medicine**: The traditional Chinese medicine sector outperformed the Shenwan Pharmaceutical Index last week but has underperformed year-to-date. Key companies to watch include Guizhou BaiLing and Wanbangde [2][11] 7. **CRO Sector Outlook**: The CRO sector is expected to benefit from supportive domestic policies and a gradual recovery in investment, with positive changes in CDMO (Contract Development and Manufacturing Organization) business anticipated [4][17] 8. **Medical Device Sector Performance**: Recent data from companies like Lepu Biotech shows significant clinical effectiveness, with overall survival (OS) of 13.8 months and progression-free survival (PFS) of 5.9 months in treatments [4][12] 9. **Regulatory and Policy Impacts**: The focus on policy-friendly enterprises in the traditional Chinese medicine sector and the impact of outpatient policy advancements on pharmacy performance are critical [2][11] 10. **Investment Strategy**: The investment strategy emphasizes identifying companies with strong Q3 performance, focusing on innovative drugs, and returning to a leadership-driven selection process [2][9][10] Additional Important Insights - **Emerging Trends in Medical Devices**: The medical device sector is experiencing a downturn, but long-term trends include a focus on domestic substitution and internationalization [4][18] - **CRO and Medical Services Performance**: The CRO sector has seen a decline recently but remains ahead year-to-date, while the medical services sector is under pressure but may recover as consumer spending increases [4][17] - **Future of PD-L1S**: PD-L1S shows consistent performance in first and second-line therapies, indicating potential market expansion opportunities [4][13] - **Recent Transactions in Generic Drugs**: The generic drug sector saw a slight decline, but significant transactions, such as Hansoh Pharma's licensing deal with Roche, highlight ongoing activity in the market [4][15] This summary encapsulates the key insights and trends discussed in the conference call, providing a comprehensive overview of the current state and future outlook of the pharmaceutical and medical device industries.

Core Insights - The overall performance of the Shenwan Pharmaceutical Index decreased by 2.48% week-on-week, outperforming the ChiNext Index but underperforming the CSI 300 Index during the week of October 13-17 [1] - The report discusses the future potential of two drugs, GST-HG131 and GST-HG141, developed by Guangshentang [1] Recent Market Review - The market experienced wide fluctuations, with banks and coal sectors leading gains, while the pharmaceutical sector mirrored the overall market trend [2] - A notable rebound was observed in innovative drug stocks that had previously seen significant adjustments, driven by individual stock logic such as performance and ESMO data [2][3] Reasoning Behind Market Movements - Geopolitical concerns have led to a period of wide market fluctuations and a shift in investment styles [3] - The underlying industry logic remains unchanged, and as trading issues are digested, innovative drug stocks are expected to regain traction [3] - There is a perception of irrationality and pessimism in the market, but as the trading structure improves, new catalysts may emerge for innovative drugs [3] Future Outlook - In the short to medium term, the focus will be on identifying pharmaceutical stocks with strong Q3 performance and preparing for a potential rebound in Q4 [4] - The report emphasizes a continued optimistic outlook for innovative drugs through 2025, with key themes including overseas large pharmaceuticals, small and medium-sized tech revolutions, and the revaluation of generic drugs [4] Strategic Allocation Insights - For innovative drugs, recommended stocks include major players like Innovent Biologics, 3SBio, and BeiGene, as well as smaller biotech firms focusing on cancer treatments and gene therapies [4][5] - New technologies such as brain-computer interfaces and AI in healthcare are highlighted as areas of interest, with companies like Xunyi Medical and JD Health being noted [6] - Internationalization of medical devices is also a focus, with companies like Senhong International and Furuida being mentioned [7] - Other strategic areas include the integration of large groups with smaller companies and the ongoing reforms in state-owned enterprises [8]

新京报贝壳财经讯 10月17日，企查查APP显示，近日，广生合癀（漳州）医药有限公司成立，法定代 表人为黄晓航，注册资本为5000万元，经营范围包含：药品批发；第三类医疗器械经营；食品销售；保 健食品（预包装）销售；食品互联网销售（仅销售预包装食品）等。企查查股权穿透显示，该公司由广 生堂、片仔癀全资子公司福建片仔癀健康科技有限公司共同持股。 ...

Core Viewpoint - Guangsheng Hehuang (Zhangzhou) Pharmaceutical Co., Ltd. has been established with a registered capital of 50 million yuan, indicating a strategic move in the pharmaceutical and healthcare sector [1] Company Summary - The legal representative of the newly established company is Huang Xiaohang [1] - The company's business scope includes drug wholesale, third-class medical device operation, food sales, health food (pre-packaged) sales, and online sales of pre-packaged food [1] - The company is jointly owned by Guangsheng Tang and Fujian Pianzaihuang Health Technology Co., Ltd., a wholly-owned subsidiary of Pianzaihuang [1]